Doxy-PEP (doxycycline post-exposure prophylaxis) is a prevention strategy where you take a single 200 mg dose of the antibiotic doxycycline after sex to reduce your risk of getting certain bacterial STIs, specifically syphilis, chlamydia, and gonorrhea. The CDC released formal clinical guidelines for its use in 2024, making it the first antibiotic-based tool specifically recommended for STI prevention in the U.S.
How Doxy-PEP Works
Doxycycline is a long-established antibiotic in the tetracycline family. It works by blocking bacteria from building the proteins they need to survive and multiply. When you take a dose shortly after a potential exposure, the drug reaches mucosal tissues (the lining of the throat, rectum, and genitals) at concentrations high enough to kill bacteria before an infection can take hold.
A single 200 mg dose maintains effective drug levels against chlamydia and syphilis bacteria for roughly three to four days. For gonorrhea, the effective window is shorter, closer to two days, which partly explains why the strategy works less reliably against that particular infection.
How to Take It
The protocol is straightforward: take 200 mg of doxycycline as soon as possible after oral, anal, or vaginal sex, and no later than 72 hours afterward. Even if you have sex multiple times in one day, you take only one dose per 24-hour period.
To reduce the chance of stomach upset or throat irritation, take it on a full stomach with a full glass of water. Avoid lying down for at least an hour afterward, since the pill can irritate the esophagus if it doesn’t move through quickly.
Who It’s Recommended For
The 2024 CDC guidelines specifically recommend doxy-PEP for men who have sex with men (MSM) and transgender women who have had a bacterial STI in the past 12 months, as these groups face the highest rates of syphilis, chlamydia, and gonorrhea. Clinicians may also discuss it with others in these populations who are at elevated risk even without a recent STI diagnosis.
For cisgender women, the evidence is less clear. One randomized trial among cisgender women in Kenya found no significant benefit, though the reasons may have had more to do with local antibiotic resistance patterns than with biological differences. The CDC currently notes that data are insufficient to make a recommendation for or against doxy-PEP in this group.
How Effective It Is
Clinical trials consistently show strong protection against syphilis and chlamydia. In major studies, doxy-PEP reduced chlamydia infections by roughly two-thirds and syphilis by a similar margin among MSM and transgender women who used it.
Gonorrhea is the weak point. Because many gonorrhea strains are already resistant to doxycycline, the protection against gonorrhea is substantially lower and varies depending on local resistance patterns. In France, where over half of gonorrhea strains resist tetracycline-class antibiotics, trials showed little benefit. In U.S. trials the results were somewhat better but still inconsistent. Doxy-PEP should not be considered a reliable shield against gonorrhea.
Side Effects
Doxycycline is generally well tolerated, especially at the intermittent doses involved in PEP (as opposed to daily use). The most common side effects are gastrointestinal: nausea, vomiting, and diarrhea. In one clinical trial, gut symptoms were reported by 53% of people in the doxy-PEP group compared to 41% in the control group, though very few people (under 1%) stopped using it because of side effects.
Increased sun sensitivity is the other notable issue. Doxycycline makes your skin burn more easily under UV exposure, so sunscreen matters more on days you take it. Less commonly, the pill can cause irritation or ulceration of the esophagus, which is why the “full glass of water, stay upright” guidance exists.
The Antibiotic Resistance Trade-Off
This is the most significant concern surrounding doxy-PEP and the reason it generates debate even among public health experts who support it. Widespread, repeated antibiotic use creates evolutionary pressure on bacteria, favoring strains that can survive the drug.
Early real-world data confirm this is already happening. In King County, Washington, after doxy-PEP guidelines were introduced in mid-2023, the proportion of gonorrhea strains resistant to tetracycline among MSM jumped from about 27% to 70%. High-level resistance surged from 2% to 65%. This rapid shift means the already-limited effectiveness of doxy-PEP against gonorrhea could erode further in communities with high uptake.
The concern extends beyond STI bacteria. Doxycycline also affects the trillions of harmless bacteria living in your gut and throat. Studies using genetic analysis found that people on doxy-PEP carried significantly more tetracycline resistance genes in their gut microbiome. In the throat, doxy-PEP users showed higher rates of colonization by resistant strep bacteria compared to nonusers (9% versus 4%).
Staph bacteria are affected too. Among doxy-PEP users in one study, tetracycline-resistant Staphylococcus aureus was found in 18% of users versus 8% of nonusers. Because resistance genes can sit on mobile pieces of DNA that hop between bacterial species, resistance that develops in harmless bacteria can potentially spread to dangerous ones.
What Doxy-PEP Doesn’t Cover
Doxy-PEP targets bacterial infections only. It offers no protection against viral STIs like HIV, herpes, hepatitis, or HPV. It also does not reliably prevent Mycoplasma genitalium infections. In fact, widespread doxy-PEP use could make Mycoplasma genitalium harder to treat in the long run, since doxycycline is already a core part of the treatment regimen for that infection and increased exposure could drive resistance.
Condoms remain the broadest-spectrum STI prevention tool available. Doxy-PEP is designed as an additional layer of protection, not a replacement for other strategies like condom use or regular STI screening.